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Background. In the era of highly active antiretroviral therapy (HAART), it remains unclear whether human
immunodeficiency virus (HIV)–infected injection drug users (IDUs) have durations of survival similar to those
for comparable HIV-uninfected IDUs. The goal of this study was to compare survival durations of HIV-infected
and HIV-uninfected IDUs for the period 1987–2004.
Methods. Demographic data, drug use characteristics, and biological markers were obtained at the time of
admission to a substance abuse treatment program. The outcome of interest was the duration of survival after
admission, and the primary exposure was HIV infection. Vital status was ascertained by means of the mortality
register by the end of 2004. Three calendar periods, which were defined on the basis of use of specific therapies,
were considered: 1987–1991 (the antiretroviral monotherapy era), 1992–1996 (the dual combination therapy era
and the era when methadone was introduced in Spain), and 1997–2004 (the era of HAART and of established
methadone programs). We used Cox regression methods allowing for late entries to handle the contribution of
persons who survived a given period and entered the following period with nonzero time. We compared HIV-
uninfected and HIV-infected IDUs with adjustments for age, sex, and duration of follow-up after admission.
Results. A total of 1209 IDUs were admitted to the hospital during the period from January 1987 through
December 2004, and 1181 were eligible for the study. The majority (81.3%) of patients were men. The mean age
( standard deviation) at admission was years, and the mean duration of injection drug use (27.8 5.6
standard deviation) was years. The prevalences of HIV and hepatitis C virus infections were 59.0% and7.6 5.0
92.3%, respectively, and the total duration of follow-up was 10.116 person-years. Although survival duration for
HIV-uninfected IDUs in 1997–2004 was similar to the duration in earlier periods, the duration for HIV-infected
IDUs improved significantly since 1997 ( ). Furthermore, among patients admitted in the last period, theP ! .01
survival durations for HIV-uninfected and HIV-infected IDUs was virtually the same (relative hazard, 0.89; 95%
confidence interval, 0.44–1.81).
Conclusions. The duration of survival of HIV-infected IDUs has improved substantially since 1997, reaching
rates similar to the rates for HIV-seronegative IDUs who accessed the health care system in the era of HAART.
Mortality rates among injection drug users (IDUs) have
been historically high and are still significantly higher
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than the rates for the general population. Frequent
causes of death among IDUs include bacterial infection,
overdose, accidents, and AIDS [1–4]. Nonetheless, co-
hort studies from Western Europe and the United States
have revealed decreased mortality rates among HIV-
infected individuals (including IDUs) in the past decade
that have resulted from the introduction of HAART
and the intensification of clinical care [5–8]. Even
though HIV-infected IDUs are less likely to start taking
HAART, their response to therapy (in terms of survival)
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is similar to that for other exposure groups, as long as adherence
to treatment is satisfactory [9, 10]. In Spain, overdose is the
primary cause of death among HIV-uninfected substance abus-
ers [11], and AIDS still accounts for an important number of
deaths. In addition, Spain has experienced one of the largest
HIV epidemics in Europe, primarily in association with injec-
tion drug use [12].
In parallel to reductions in HIV/AIDS-related mortality,
other studies have focused on the impact of harm reduction
interventions and substitution treatment with methadone on
mortality rates, which have also decreased with regard to over-
dose-related deaths [13, 14]. However, few studies have com-
pared the mortality rate among HIV-infected persons with that
among HIV-uninfected subjects who belong to the same risk
category [15, 16].
The first goal of the present study was to explore the change
over time in survival for IDUs once they are admitted to a
substance abuse treatment program. In particular, our aim was
to characterize how survival at the population level was changed
in the era of HAART, the era of improved prophylaxis, and the
era of harm reduction interventions. The second objective fo-
cused on determining whether, in the HAART era, survival rates
among HIV-infected IDUs were comparable to those among
HIV-uninfected patients.
Here, we report the mortality rates for 18 years of observation
for a cohort of IDUs who were admitted to a substance abuse
treatment program in a tertiary hospital. On the basis of the
years of introduction of methadone maintenance treatment
programs and HAART in Spain, the follow-up period was di-
vided into the following intervals: 1987–1991 (the antiretroviral
monotherapy era), 1992–1996 (the dual-combination treat-
ment era and when methadone treatment was introduced), and
1997–2004 (the era of HAART and of established methadone
programs).
PATIENTS AND METHODS
The study population comprised IDUs who were admitted to
a substance abuse treatment program at the University Hospital
Germans Trias i Pujol in Badalona (Spain) during the period
of January 1987 through December 2004. The majority of pa-
tients were injection heroin users and were referred from mu-
nicipal outpatient clinics located in Badalona and Santa Col-
oma, the 2 cities contiguous to the hospital. The criteria for
referral generally depended on the severity of addiction but not
on the person’s HIV serostatus. At admission to the substance
abuse treatment program, wide-raging information on socio-
demographic characteristics, drug use, and clinical variables was
recorded. In addition, patients underwent a comprehensive
medical examination and routine laboratory testing for bio-
logical markers, including a history of infectious diseases (e.g.,
hepatitis B), determination of immune parameters, and stan-
dard biochemistry tests (e.g., hemoglobin assessment). During
the period 1987–1991, treatment of substance abuse mainly
consisted of detoxification from heroin, followed by treatment
with opiate antagonists. Patients who reported abuse of addi-
tional drugs (i.e., cocaine, alcohol, and/or benzodiazepines)
were treated accordingly to avoid withdrawal. Starting in 1992,
methadone was the most widely used treatment, either as a
detoxification agent or as substitution therapy for long-term
heroin abusers.
In addition to surveillance through regular medical care,
follow-up information was obtained through regular linkage
with other databases, as described elsewhere [15]. Final vital
status was ascertained by a complete linkage of the whole study
cohort with the Catalonian mortality register by 31 December
2004.
The outcome of interest was the elapsed survival time from
the first admission to either death or 31 December 2004, the
end of the follow-up period, and the study considered mortality
due to all causes. The primary exposure was HIV infection.
Survival curves for HIV-uninfected and HIV-infected IDUs
were estimated using the Kaplan-Meier method and were com-
pared using the log rank test. For multivariate analysis, which
was adjusted for age and sex, comparisons were performed with
a proportional hazard regression model.
All analyses treated the 3 calendar periods as an external time
dependent covariate (i.e., period analyses) [17–19]. As men-
tioned above, the calendar periods considered were 1987–1991
(period 1), 1992–1996 (period 2), and 1997–2004 (period 3).
Using the period analysis approach, individuals contributed as
many records to the analyses as periods in which they were
observed at risk. Thus, a survival time is treated as left-truncated
(late entry) if admission to a substance abuse treatment pro-
gram occurred in a previous period, and it was right-censored
if the individual was alive at the end of the period. An important
advantage of period analysis over traditional cohort analysis is
that it furnishes up-to-date estimates of long-term survival rates
[5, 20, 21].
During follow-up, several IDUs who were HIV uninfected
at admission acquired HIV infection. The time of HIV infection
was defined by the midpoint of the interval from the last se-
ronegative test result to the first seropositive test result. These
persons who experienced seroconversion contributed survival
times to both groups of HIV infection: as seronegative subjects,
the (right-censored) survival time lasted from admission until
HIV infection; as seropositive subjects, the survival time lasted
from the duration after admission to HIV infection, until either
death or the end of follow-up.
To check the proportional hazards assumption of the mod-
els applied, we performed tests that are based on the Schoen-
feld residuals of the Cox regression model. If proportionality
372 • CID 2007:45 (1 August) • HIV/AIDS
Table 1. Baseline characteristics of 1181 injection drug users at the time of admission to a substance
abuse treatment program.
Characteristic
Calendar period
1987–1991
(n p 490)
1992–1996
(n p 393)
1997–2004
(n p 298)
Sociodemographic and drug use variables
Male sex 80.4 78.9 85.9
Age, years 25 (23–28) 27 (24–31) 31 (27–35)
History of imprisonment 42.4 34.8 48.8
Alcohol consumption 40 g/day …a 42.4 31.7
Duration of injection drug use, years 6 (4–8) 7 (3–11) 10 (5–15)
Age at first use of injection drugs, years 19 (17–22) 19 (17–23) 19 (17–23)
Biological marker
Hemoglobin concentration of !13.5 g/L for men
or 11.5 g/L for women 19.2 26.1 31.5
CD4+ cell count, cells/mL 749 (526–1052) 840 (390–1333) 768 (416–1234)
CD8+ cell count, cells/mL 796 (591–1078) 1016 (774–1386) 881 (691–1146)
HIV infection 70.0 53.4 48.3
HCV infection 91.0 94.1 92.1
HBsAg positive 10.1 5.9 6.9
NOTE. Data are median value (interquartile range) for continuous variables and relative frequency (among nonmissing
observations) for categorical variables. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
a Not recorded before 1992.
holds, these residuals are distributed randomly along the sur-
vival time [22].
Statistical analyses were performed using the statistical soft-
ware R (in particular, the Event History Analysis package, which
accomplishes survival analysis in the framework of period anal-
ysis [23]). Test results were considered to be statistically sig-
nificant if the resulting P value was !.05.
RESULTS
From January 1987 through December 2004, a total of 1209
IDUs were admitted for the first time to a substance abuse
treatment program. Twenty-eight (2.3%) of these subjects
were excluded from the study cohort because their HIV se-
rostatus was unknown; these were mainly individuals who left
the detoxification unit the day after admission. Admission
numbers, according to the calendar periods, for the remaining
1181 subjects included in the study were as follows: 490 sub-
jects (41.5%) for 1987–1991 (period 1), 393 subjects (33.3%)
for 1992–1996 (period 2), and 298 subjects (25.2%) for 1997–
2004 (period 3).
The baseline characteristics of the 1181 IDUs are presented
in table 1. According to calendar period, the median age (25,
27, and 31 years for periods 1–3, respectively) and median
duration of injection drug use (6, 7, and 10 years for periods
1–3, respectively) increased over time, whereas the median age
at which drugs were first injected remained constant (19 years
for all periods). The proportions of male IDUs and of subjects
with past history of imprisonment were lowest in period 2
(78.9% and 34.8%, respectively) and highest in period 3 (85.9%
and 48.8%, respectively). With respect to biological markers, a
constant prevalence of hepatitis C virus (HCV) infection
(190%) and a decreasing prevalence of HIV infection (from
70.0% to 48.3%) were observed. Among the IDUs who were
HIV uninfected at the time of admission, 48 (10.1%) became
infected with HIV during the follow-up period.
Table 2 shows the baseline characteristics of individuals seen
at different periods, as stratified by calendar period and HIV
status. Approximately one-third of HIV-infected IDUs were
receiving antiretroviral treatment at the time of admission; these
rates were consonant, with moderately high CD4+ cell counts
noted at admission among HIV-infected subjects. Specifically,
75% of these patients had a baseline CD4+ cell count greater
than 480, 310, and 265 cells/mL in periods 1–3, respectively.
The term “admissions in period” refers to IDUs who were
admitted to a substance abuse treatment program during the
period. Thus, the differences between these numbers and the
total number of IDUs seen during a period involve subjects
who had started undergoing treatment in a previous period
and who survived until the beginning of the present period.
Mortality rates were highest during the second period and low-
est during the third period, and HIV-infected individuals had
higher mortality rates than did HIV-uninfected individuals.
Mortality rates for the 3 periods are depicted in figure 1 by
means of the extended Kaplan-Meier estimates of the survival
curves (i.e., the estimates that incorporated late entries). Max-
imum durations of follow-up were 5 years (1987–1991), 10
Table 2. Baseline characteristics of injection drug users, according to HIV infection status and calendar period.
Characteristic
Calendar period
1987–1991 1992–1996 1997–2004
HIV-uninfected
patients
HIV-infected
patients
HIV-uninfected
patients
HIV-infected
patients
HIV-uninfected
patients
HIV-infected
patients
No. of subjects seen 147 363a 303 548a 415 544a
Admissions during period, % of patients 100 100 60.4 41.8 37.1 28.1
Male sex, % of patients 83.0 79.1 83.8 78.1 84.6 78.1
Date of admission 1989.7 1989.6 1992.9 1991.4 1995.3 1993.7
Age, years 25 (22–29) 25 (23–28) 26 (23–29) 26 (23–30) 27 (24–31) 28 (24–32)
Age at first use of injection drugs, years 20 (17–23) 18 (16–21) 20 (18–24) 18 (16–21) 20 (18–24) 18 (16–21)
CD4+ cell count, cells/mL 930 (692–1302) 660 (480–971) 1235 (900–1548) 540 (310–821) 1215 (904–1475) 507 (265–732)
CD8+ cell count, cells/mL 841 (608–1030) 784 (590–1100) 960 (750–1189) 900 (640–1263) 903 (704–1159) 942 (690–1297)
Antiretroviral treatment, % of patients NA …b NA 32.6 NA 37.4
Total time at risk, no. of person-years 301.5 850.0 958.8 1886.2 2672.3 3446.6
No. of deaths 7 44 23 157 38 110
Mortality rate, no. of deaths per 100 person-years 2.32 5.18 2.40 8.32 1.42 3.20
NOTE. Data are median value (interquartile range) for continuous variables and relative frequency (among nonmissing observations) for categorical variables, unless otherwise indicated. NA, not
available.
a Includes 20 patients (1987–1991), 19 patients (1992–1997), and 9 patients (1997–2004) who experienced seroconversion.
b Not recorded before 1992.
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Figure 1. Kaplan-Meier estimates of survival during 1987–1991 (A),
1992–1996 (B), and 1997–2004 (C). RH, relative hazard; +, positive; ,
negative.
Figure 2. Kaplan-Meier estimates of survival during 1997–2004, ac-
cording to the year of admission to a substance abuse treatment program.
+, Positive; , negative.
years (1992–1996), and 18 years (1997–2004). Although, during
each of the 3 periods, the durations of survival for HIV-infected
IDUs were worse than those for HIV-uninfected patients
( , , and for periods 1–3, respectively,Pp .047 P ! .001 P ! .001
by log rank test), the survival durations for HIV-infected IDUs
have improved significantly since 1997 ( ). By contrast,P ! .01
the duration of survival for HIV-uninfected IDUs in 1997–
2004 was similar to that in earlier periods. This is reflected by
a lower (unadjusted) relative hazard for period 3 (2.34; 95%
CI, 1.62–3.39), compared with period 2 (3.39, 95% CI, 2.18–
5.25). Figures 1B and 1C illustrate the observed diminished
differences between both groups.
To further characterize survival in the era of HAART (1997–
2004), we stratified the group according to whether patients
were admitted to the substance abuse treatment program dur-
ing that period. Figure 2 demonstrates that the survival du-
rations for HIV-uninfected and HIV-infected IDUs who were
admitted after the introduction of HAART in 1997 were very
similar ( ) during the available maximum follow-upPp .75
time of 8 years; it also shows that the only patient group with
poor survival was that of HIV-infected patients who were ad-
mitted to the detoxification program during periods preceding
1997. Figure 2 clearly shows that differences in survival for
HIV-infected individuals who were admitted to the program
during the pre-HAART era were nullified by those for patients
who were admitted during the HAART era.
To assess the statistical significance of the differences between
HIV-uninfected and HIV-infected individuals over calendar pe-
riods, table 3 shows the results of proportional hazards models
that adjusted for age and sex. There were no significant dif-
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Table 3. Cox regression models including HIV serostatus, sex,
and age in injection drug users who were admitted to a substance
abuse treatment program during 1987–2004.
Period, variable Coefficient
Relative hazard
(95% CI) P
1987–1991 (n p 510)
HIV infection 0.799 2.224 (0.999–4.952) .05
Male sex 0.147 0.864 (0.447–1.667) .662
Age 0.040 1.041 (0.975–1.111) .225
1992–1996 (n p 851)
HIV infection 1.217 3.379 (2.178–5.243) !.001
Male sex 0.337 1.401 (0.931–2.108) .106
Age 0.069 1.071 (1.040–1.103) !.001
1997–2004 (n p 959)
HIV infection 0.844 2.326 (1.603–3.373) !.001
Male sex 0.379 1.462 (0.927–2.305) .103
Age 0.036 1.037 (1.005–1.070) .022
1997–2004 (n p 307)a
HIV infection 0.114 0.892 (0.441–1.807) .752
Male sex 0.356 1.427 (0.434–4.696) .559
Age 0.023 1.024 (0.962–1.089) .457
a Restricted to patients admitted to a substance abuse treatment program
during the period.
ferences between male and female IDUs, and the risk of dying
increased with increasing age in periods 2 ( ) and 3P ! .001
( ). More importantly, at the bottom of table 3, wePp .022
show that there were no significant differences between HIV-
uninfected and HIV-infected IDUs during the HAART era,
when we restricted attention to persons who were admitted to
the program during that era. Testing for proportional hazards
showed that assumptions hold reasonably well ( for allP 1 .05
models).
DISCUSSION
This study of patients at risk of AIDS and of drug-related
complications found that survival durations for HIV-infected
IDUs have improved substantially since 1997, reaching rates
similar to those for HIV-seronegative persons who accessed the
health care system in the era of HAART and substance abuse
treatment (figure 2). Comparable findings were described by
Wang et al. [16], who reported similar survival durations for
HIV-uninfected IDUs and HIV-infected IDUs with CD4+ cell
counts of 1350 cells/mL.
Because only one-third of the HIV-infected IDUs in our
study received HAART, other factors are likely to have con-
tributed to the improved survival among contemporary HIV-
infected heroin users—namely, access to substitution therapy
with methadone, prophylaxis for opportunistic infections,
harm reduction interventions, and regular clinical care, as
shown by previous studies [24].
The differences in survival duration between HIV-unin-
fected and HIV-infected IDUs also held when we adjusted the
proportional hazards regression models for additional covar-
iates, such as a history of imprisonment, duration of injecting
drug use, hemoglobin concentration, and HCV infection. An-
derson et al. [25] stated that HCV-HIV coinfection increased
the risk of death among HIV-infected individuals. The present
study could not confirm this finding in our cohort of IDUs,
because nearly 95% of all HIV-infected IDUs were also in-
fected with HCV.
A recent study by Lucas et al. [26] focused on the association
between patterns of drug use (i.e., nonuse, intermittent use,
and persistent use) and HIV-1 disease progression. The authors
reported a better duration of survival among intermittent drug
users than among persistent drug users. Although, in our study,
all patients were persistent drug users before admission, the
pattern of use during and after drug abuse treatment was sub-
ject to high variability; this may have contributed to the im-
proved survival shown here. One of the strengths of the present
study is the time axis for our analysis (i.e., the number of years
since the admission to a substance abuse treatment program),
because this analysis defines a well-known starting point avail-
able for all study participants that is independent of the HIV
serostatus of the patients. Another strong point is the com-
pleteness of follow-up. Specifically, we performed an exhaustive
linkage of the complete database of 1181 patients with the
Catalonian mortality register.
HAART has been proven to be an extremely effective therapy
for HIV-infected individuals. We have shown that HIV-infected
IDUs who received health care during the period 3 exhibited
mortality rates comparable to those for IDUs who were not
infected with HIV. In contrast, HIV-infected IDUs who were
admitted to the health care system before 1997 did experience
higher mortality rates. This may be explained in part by sub-
optimal treatment strategies before the HAART era, with sub-
sequent treatment failure and pharmacological resistance once
the individuals reached the period in which HAART became
available.
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